By design and function, our novel biotech will disrupt the projected ‘25 $130B in vitro diagnostics (IVD) industry by two impacts. First, the technology is a first-in-class, safe, non-invasive, nuclear medicine, and molecular imaging (NMMI) diagnostic with proven Phase I and II clinical results showing an efficacy 5x greater than the US standard, which is limited to 50 microns. Its focus is on pulmonary and vascular diseases.
In concert, the development of a predictive AI epidemiology platform. When adapting real-world evidence (RWE), that combines digital data and analytics with traditional testing, it creates new clinical insights and more efficient workflows. The result is a better patient outcome by reducing wrongful diagnoses and misdiagnoses attributed to $750 billion in economic costs and loss of productivity.
Hence, becoming an industry “gold standard” solution provider.
As a showcase company at the Brussels Pharma Partnering Summit, we drew considerable interest from international clinical research organizations (CROs) and industry pharma business development and commercialization relationship firms. To date, the following is our operating status and milestones:
- Through our CRO strategic partner Clinexel Life Sciences, a fast-track Phase III clinical trial. Sponsorship and support from the Indian government's Biotechnology Industry Research Assistance Council, (BIRAC), in the form of up to 50% of development costs, with no ceiling, through 2030. The WHO has identified 200M in India as the unmet need for patient detection and monitoring.
- The World Health Organization sponsors the commercialization and distribution of NMMI-type TB and COPD derivatives throughout the continent. For TB alone, the TB unmet need is 12,500,000. A recently announced COPD patient care campaign seeks innovative technologies to overcome the crisis.
- US-based Navitas Life Sciences, another CRO global partner, will start FDA approval process allowing us to commercialize and distribute a COPD device that elevates blood oxygen levels to enhance nitric oxide (NO) within the vascular system. NO is a first-line defender against pulmonary disease impact.
- Navitas will also implement our TB and COPD diagnostic FDA approval and US patent registration requirements.
- Resulting from our EU MedTech device patent partnership, we gain commercial distribution rights in the US, EU, India, the ME, and Africa. Others to be added over the next five years.
- In a recent JAMA modeling study, global COPD prevalence is projected to approach 600 million cases worldwide by 2050,
Ready to Ask For Funding for your company?
Post a Funding Request